Swiss pharmaceutical company Roche has announced that a new antibiotic, zosurabalpin, is progressing to phase 3 testing.

Roche (RHHBY) is planning to move a new antibiotic into late stage clinical trials after early studies showed it had ...

Trans-Tasman drug developer Aft Pharmaceuticals is targeting lucrative niche diseases its Big Pharma rivals have ignored ...

Outset Ventures, the Auckland-based venture firm and incubator that spun out deep tech unicorns like Rocket Lab and LanzaTech ...

Complete Zealand Pharma A/S ADR stock information by Barron's. View real-time ZLDPY stock price and news, along with industry-best analysis.

The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body ...

Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to ...

Biotechs have faced several challenging years with slumping valuations and a competitive funding environment. However, the latest slew of ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

Zealand Pharma A/S, a biotechnology company, has appointed Steven Johnson as Chief Development Officer.

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

“We are incredibly excited to launch this partnership, which represents a step change to realize Zealand Pharma's vision of becoming a key player in the future management of obesity. Roche ...